The company operates across three segments: Branded Pharmaceuticals, Generic Pharmaceuticals, and Injectable Pharmaceuticals. Revenue is driven primarily by generic injectable products (41.8%), oral generics (32.8%), and branded drugs (24.68%), with North America accounting for 61.1% of sales and Middle East/North Africa representing 31.5%.
Cyborg Score Rationale
Hikma is actively launching new products, signing partnerships, investing in R&D, building new manufacturing plants, and deploying capital through acquisitions. The company generates majority revenue from its generics and injectables segments supported by manufacturing facilities across markets. Strong cash flow and dividend yield support continued execution.
Top Insights
January 2026: Launched Enoby™ and Xtrenbo™ (denosumab biosimilars) referencing blockbuster originals
April 2025: Acquired Novugen for kinase inhibitor cancer medication capabilities
Operates 29 manufacturing plants enabling scaled production across injectable, oral, and respiratory formats
Maintains attractive 4% dividend yield supporting income investors
Named Competitors
Lupin — Global generic and specialty pharmaceutical manufacturer
Teva Pharmaceuticals — Generic and specialty pharmaceutical company
Mylan — Generic and specialty pharma products
Sandoz — Generics and biosimilars division
Recent Developments
(January 2026) Launched denosumab biosimilars Enoby™ and Xtrenbo™
(January 2026) Achieved B scores in Climate Change and Water Security in CDP assessment
(April 2025) Completed acquisition of Novugen for oncology pipeline expansion
Open the full interactive Hikma Pharmaceuticals PLC report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.